Impact of Genomic Alterations on Efficacy of Trastuzumab Deruxtecan Against Human Epidermal Growth Factor Receptor-2–Positive Advanced Gastric Cancer This was a prospective, cross-sectional, ...
Different genomic alterations in DNA damage repair (DDR) pathways occur in 20% to 25% of advanced prostate cancer, including homologous recombination repair (HRR) gene alterations. Identifying the ...
Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...
The Association for Molecular Pathology announced the publication of best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency (HRD) testing ...
AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen a ...
TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...
Illustration showing how autophagy induction increases the efficiency of precise gene editing. In normal cells, DNA breaks caused by CRISPR–Cas9 are frequently repaired through non-homologous end ...
Please provide your email address to receive an email when new articles are posted on . Adding niraparib to abiraterone acetate and prednisone lowered risk for cancer growth by 37% among certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results